Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced a proposed underwritten public offering of common shares and, to certain investors, pre-funded warrants to purchase common shares. The company will grant underwriters a 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. Jefferies LLC, Leerink Partners, and Evercore ISI are acting as joint bookrunning managers for the offering. MindMed plans to use net proceeds to fund research and development of its product candidates, as well as for working capital and general corporate purposes. The offering will be made under a shelf registration statement filed with the Securities and Exchange Commission. Final terms will be disclosed in a prospectus supplement to be filed with the SEC.